Literature DB >> 18158478

Acute heart failure with preserved systolic function.

Rahul Kumar1, Sanjay K Gandhi, William C Little.   

Abstract

Many patients with acute heart failure have marked hypertension and preserved left ventricular ejection fraction. In these patients, the heart failure usually does not result from transient systolic dysfunction or valvular abnormalities but rather results from diastolic dysfunction. Treatment of this condition includes control of hypertension, cautious diuresis, and, if necessary, ventilatory support. Further workup after the acute phase should be directed by the overall clinical picture. Other potential contributing factors, such as renal artery stenosis, valvular heart disease, and ischemia, should be strongly considered. Unfortunately, chronic therapy for diastolic heart failure has not yet been standardized due to the paucity of clinical trial data. Strict control of hypertension appears to be of paramount importance. Angiotensin-converting enzyme inhibitors or receptor blockers may be of benefit in preventing repeat hospitalizations.

Entities:  

Mesh:

Year:  2008        PMID: 18158478     DOI: 10.1097/01.CCM.0000296271.08591.D2

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  3 in total

Review 1.  [Left ventricular diastolic dysfunction. Implications for anesthesia and critical care].

Authors:  R Meierhenrich; W Schütz; A Gauss
Journal:  Anaesthesist       Date:  2008-11       Impact factor: 1.041

2.  7th Brazilian Guideline of Arterial Hypertension: Chapter 14 - Hypertensive Crisis

Authors:  M V B Malachias; E C D Barbosa; J F V Martim; G B A Rosito; J Y Toledo; O Passarelli
Journal:  Arq Bras Cardiol       Date:  2016-09       Impact factor: 2.000

3.  Swimming-Induced Pulmonary Edema: Evaluation of Prehospital Treatment With CPAP or Positive Expiratory Pressure Device.

Authors:  Claudia Seiler; Linda Kristiansson; Cecilia Klingberg; Josefin Sundh; Annika Braman Eriksson; Daniel Lundeqvist; Kristofer F Nilsson; Maria Hårdstedt
Journal:  Chest       Date:  2022-03-11       Impact factor: 10.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.